2026-10-15

Rocket Lab (RKLB) Stock Sinks Nearly 20% in Two Days as Neutron Rocket's First Launch Slips to 2027

Written & reviewed by the TradeSmrt editorial team · 2026-10-15

In this article

What Happened
Why This Delay Stings More Than It Should - Story Stocks and Hardware Risk
What to Take Away From This
FAQ
Sources

What Happened

On October 14, Rocket Lab (Nasdaq: RKLB) confirmed that the debut launch of its larger, reusable Neutron rocket is being pushed back to 2027. Just months earlier, the company had been targeting a fourth-quarter 2026 launch - a goal it has now officially abandoned. The market's reaction was swift and severe. Shares, which had closed at $64.22 the previous day, fell 7.8% to $59.18 on the day of the announcement, then kept sliding in after-hours trading. The decline didn't stop there: on October 15, RKLB extended its losses with an intraday drop of roughly 12-13%, trading in a wide range between $49.69 and $55.21 and changing hands around the low-$50s. Measured from the October 13 close, that's a two-day decline of close to 19%.

The cause was a hardware defect, not a scheduling choice made for its own sake. Rocket Lab founder and CEO Peter Beck said engineers discovered voids - small air pockets - in the forward dome of Neutron's first-stage propellant tank, a component made from carbon composite material, while building the actual vehicle intended for the first flight. Beck was careful to note the flaw wouldn't cause the dome to rupture outright, but the company reaffirmed a simple rule: it won't fly without a full safety margin, and that principle outweighed the pressure to hit a near-term launch date. A replacement dome is now in production and must clear ultrasonic testing before being installed on flight hardware. Beck said he expects the production and testing steps to wrap up before the first quarter of 2027, with final integration completing sometime during that quarter - after which the company will set a firmer launch date.

This isn't the first time Neutron's timeline has slipped. The rocket was originally targeted for a second-half 2025 debut, then pushed to the first quarter of 2026, then to the fourth quarter of 2026, and now to 2027 - more than a year later than the original plan. Compounding the concern, this delay traces back to the same system - the first-stage propellant tank - that suffered a separate failure in January 2026, when a tank ruptured during a pressure test. Wall Street's response was mixed but leaned negative. Several firms, including KeyBanc Capital Markets and Clear Street, trimmed their price targets following the announcement, and some analysts widened their 2026 loss estimates for the company. Not every analyst turned bearish, though - Cantor Fitzgerald, for one, reiterated an Overweight rating, arguing the long-term growth story remains intact even with the setback.

Why This Delay Stings More Than It Should - Story Stocks and Hardware Risk

To understand the stock's reaction, start with where Rocket Lab's actual revenue comes from today. The company's current sales are driven almost entirely by its small Electron rocket - which has already completed well over 90 successful launches - and its Space Systems division, which builds satellite components and spacecraft. Neutron, by contrast, has never flown. Yet it's the primary reason bulls assign Rocket Lab a valuation well above what its current business alone would justify. Neutron is a reusable, medium-lift rocket designed to compete directly with SpaceX's workhorse Falcon 9, chasing U.S. national security launch contracts and large satellite-constellation deployment deals. In short, Rocket Lab's stock price is less a bet on what Electron earns today and more a bet on what Neutron could earn tomorrow.

In that kind of structure, a launch delay isn't just a scheduling update - it's an event that directly undermines the core assumption behind the valuation. What worries investors most isn't any single delay but the pattern. One slip could be chalked up to bad luck; a sequence running from second-half 2025, to Q1 2026, to Q4 2026, and now to 2027 raises a more fundamental question about whether the company has the execution capability to build a much larger, more complex vehicle on a reliable schedule. The fact that this latest defect sits in the same system - the first-stage propellant tank - that failed during a pressure test back in January only reinforces the read that this may not be isolated bad luck, but a recurring weak point in that component's design or manufacturing process.

This also highlights a structural difference between hardware and software risk. A software bug can be patched and redeployed within hours. A rocket, especially one where a microscopic void in a carbon-composite tank can mean catastrophic failure, cannot be governed by a "ship now, fix later" mentality - "wait until the safety margin is right" is a rule companies in this industry cannot afford to break. That's the correct, safety-first call, but it also transmits genuine schedule uncertainty directly into the stock price, since nobody - including the company - can say with precision when the fix will be fully validated. With SpaceX already dominating the reusable-rocket market through Falcon 9's track record and pulling ahead with Starship development, every additional quarter Neutron slips raises the stakes on whether Rocket Lab is ceding a first-mover window it may not get back.

There's also an asymmetry worth noting between the financial impact and the stock reaction. Some analysts point out that Neutron was only ever planned to fly once in its debut year, meaning the near-term revenue hit from this specific delay is smaller than the stock move might suggest. But share prices react to narrative credibility as much as to revenue models. Every slip pushes back the point at which Neutron is expected to reach a steady launch cadence - several flights per year - which in turn pushes back the future cash flows that underpin any discounted-cash-flow valuation of the stock. The cleanest way to read this selloff, then, isn't "the market now believes Neutron will never fly," but rather "the market just raised the discount rate it applies to Rocket Lab's ability to execute on time."

What to Take Away From This

"Story stocks" built on a future product are exquisitely sensitive to single events. When most of a company's valuation rests on a product that hasn't shipped yet - rather than current revenue - even a narrowly technical update can move the stock sharply. For these names, track how confidence in eventual delivery evolves over time, not just the headline date itself.
Read repeated delays as a pattern, not a one-off news item. A single schedule slip can be bad luck; recurring problems in the same system or component are a signal worth treating as a structural risk rather than noise. Keeping a simple timeline of a company's past delays makes this pattern easier to spot before the market fully re-prices it.
Hardware risk and software risk are not the same animal. In physical products - especially aerospace, where safety margins are non-negotiable - "launch fast and iterate" simply isn't an option. When investing in hardware-dependent companies, it's reasonable to assume some baseline of schedule slippage, and to judge the company less on whether delays happen and more on how transparently it discloses the specific cause and a concrete remediation timeline, as Rocket Lab did here.
When analysts split on the same news, dig into their reasoning rather than just counting votes. Some firms cut price targets while others held an Overweight rating through the same announcement - usually because they weigh near-term momentum differently from long-term fundamentals. Figuring out which logic better matches your own investment horizon matters more than tallying upgrades versus downgrades.
Pre-identify the next checkpoint after a sharp drop. For Rocket Lab, that's the next earnings report, expected November 9, which should bring updated capex and guidance. Knowing that date in advance makes it easier to prepare for further volatility or to build a more structured view of bounce-back versus further-downside scenarios.

FAQ

Doesn't Rocket Lab still generate revenue without Neutron?

Yes. Rocket Lab's current revenue comes mostly from its small Electron rocket, which has already completed more than 90 successful launches, and its Space Systems division, which builds satellite components and spacecraft. But the premium valuation investors assign to the stock is largely built on Neutron's future revenue potential - national security launch contracts and large satellite-constellation deals - which is why delays to a rocket that hasn't even flown yet can still move the share price sharply.

Does this delay signal a financial health problem at Rocket Lab?

The announcement itself stems from a manufacturing defect - microscopic voids in a carbon-composite propellant tank - not a financial issue. That said, the longer Neutron's commercialization is pushed back, the longer the company has to fund research, development, and production costs without the revenue that vehicle is expected to eventually generate, so cash burn and future financing plans are worth watching closely.

If Neutron eventually launches successfully, will the stock recover?

The success of the first launch and, just as importantly, how quickly the company reaches a steady launch cadence afterward are the key variables. Historically, new rockets have often needed additional time after a successful debut flight before production and launch rates stabilize. A successful first launch could act as a near-term positive catalyst, but a lasting valuation recovery depends on Neutron actually delivering on the launch volumes and contracts the company has promised.

Sources

This article is an original synthesis and analysis based on the reporting below, not a reproduction of the original articles. Please check the sources directly for the latest exact figures.

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly, so please verify the latest data before making any investment decisions.